QQ客服 官方微博 反馈留言

	First-Line Radical Local Therapy May Provide Additional Survival Gain for Patients with EGFR-Mutant Metastatic NSCLC Receiving TKIs
	Lu, X.; Wang, J.; Wang, C.; Bi, N.; Zhou, Z.; Wang, Y.; Wang, L.
	2018
卷号	13期号:10页码:S892-S892
关键词	Tyrosine kinase inhibitors non-small cell lung cancer Radical local therapy
ISSN号	1556-0864
DOI	10.1016/j.jtho.2018.08.1625
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6350485
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Lu, X.,Wang, J.,Wang, C.,et al. First-Line Radical Local Therapy May Provide Additional Survival Gain for Patients with EGFR-Mutant Metastatic NSCLC Receiving TKIs[J],2018,13(10):S892-S892.
APA	Lu, X..,Wang, J..,Wang, C..,Bi, N..,Zhou, Z..,...&Wang, L..(2018).First-Line Radical Local Therapy May Provide Additional Survival Gain for Patients with EGFR-Mutant Metastatic NSCLC Receiving TKIs.,13(10),S892-S892.
MLA	Lu, X.,et al."First-Line Radical Local Therapy May Provide Additional Survival Gain for Patients with EGFR-Mutant Metastatic NSCLC Receiving TKIs".13.10(2018):S892-S892.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。